Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTO 328 plus best supportive care vs best supportive care in multicentric Castleman's disease
2009-012380-34Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multicentric angiofollicular lymphoid hyperplasia (MCD) comparing CNTO 328 plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Durable tumor and symptomatic response. Started Sep 2009; status: completed.
02
Drugs
siltuximab
03
Conditions
multicentric angiofollicular lymphoid hyperplasia (MCD)
Beyond the preview
Go deeper on 2009-012380-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012380-34.